Related Experiment Video
Updated: Sep 15, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
A population-based observational study using statistical modeling to assess the association between depressive
1Department of Public Health Science, Graduate School and Transdisciplinary Major in Learning Health Systems, Graduate School, Korea University, 145, Anam-Ro, Seongbuk-Gu, Seoul, 02841, Republic of Korea.
Background:
This study aimed to investigate the association between depressive symptom severity and sleep disorders in postmenopausal women.
Methods:
This observational study included data from 4808 postmenopausal women derived from a nationally representative sample in the USA. Depressive symptom severity was assessed using the Patient Health Questionnaire-9, while sleep disorders were identified based on self-reported physician diagnoses. Weighted multivariable logistic regression models were used to analyze the association between depressive symptom severity and sleep disorders, adjusting for potential confounders. Restricted cubic splines were applied to evaluate possible nonlinear relationships, and subgroup analyses were conducted across key sociodemographic, health, and behavioral factors. Additionally, Lasso regression and logistic regression were used to identify the most influential predictors of sleep disorders. Supplementary and sensitivity analyses were performed using alternative sleep outcomes and modified depressive symptom scales to test robustness and item-level overlap.
Results:
Depressive symptom severity was positively associated with sleep disorders, demonstrating a dose-response relationship (P for trend < 0.001). Each unit increase in depressive symptom score was associated with a 10% higher risk of sleep disorders (OR = 1.10, 95% CI: 1.07-1.13). RCS analysis confirmed a linear association (P for nonlinear = 0.4696). Subgroup analyses identified CVD as a significant effect modifier (P for interaction = 0.019), with a stronger association in individuals with CVD (OR = 1.11, 95% CI: 1.09-1.13) compared to those without (OR = 1.07, 95% CI: 1.03-1.11). Lasso and logistic regression analyses consistently ranked depressive symptoms as the strongest predictor of sleep disorders. The association remained robust and specific across both supplementary outcomes and sensitivity models using modified depressive symptom scales.
Conclusions:
This study demonstrated a linear dose-response association between depressive symptom severity and sleep disorders in postmenopausal women, which was further amplified among individuals with CVD. Depressive symptoms were identified as the most critical predictor, underscoring the importance of mental health in managing sleep health. These findings highlight the need for integrated interventions combining mental health screening, lifestyle modifications, and community-based care approaches to mitigate the dual burden of depressive symptoms and sleep disorders in this vulnerable population.
More Related Videos
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
05:59Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
Related Concept Videos
Depressive Disorders: MDD and Dysthymia
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depression: Overview
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...